Blacklight

The Sanford guide to antimicrobial therapy 2021 /

Title:
The Sanford guide to antimicrobial therapy 2021 /
Format:
Book
Institution:
MCPHS Boston, MCPHS Worcester
Contents:
Abbreviations -- Table 1. Clinical approaches to initial choice of antimicrobial therapy -- Table 2. Recommended antimicrobial agents against selected bacteria -- Table 3. Suggested duration of antibiotic therapy for selected clinical syndromes in immunocompetent patients -- Table 4A. Antibacterial activity spectra -- Table 4B. Antifungal activity spectra -- Table 4C. Antiviral activity spectra -- Table 5A. Treatment options for systemic infection due to multi-drug resistant gram-positive bacteria -- Table 5B. Antibacterial treatment: presumed or confirmed Enterobacterales producing extended-spectrum beta-lactamases (ESBL) -- Table 5C. Suggested specific antibacterial therapy : carbapenem-resistant Enterobacterales -- Table 5D. Suggested specific antibacterial therapy : highly resistant Pseudomonas aeruginosa -- Table 6. Suggested management of suspected or culture-positive Methicillin-resistant S. aureus infections -- Table 7. Antibiotic hypersensitivity reactions & drug desensitization methods -- Table 8. Pregnancy risk and safety in lactation -- Table 9A. Selected pharmacologic features of antimicrobial agents -- Table 9B. Pharmacodynamics of antibacterials -- Table 9C. Enzyme- and transporter- mediated interactions of antimicrobials -- Table 10A. Antibiotic dosage and side-effects -- Table 10B. Antimicrobial agents associated with photosensitivity -- Table 10C. Aminoglycoside once daily and multiple daily dosing regimens -- Table 10D. Prolonged or continuous infusion dosing of selected antibiotics -- Table 10E. Inhalation antibiotics -- Table 11A. Treatment of fungal infections -- Table 11B. Antifungal drugs : Dosage, adverse effects, comments -- Table 12A. Treatment of mycobacterial infections -- Table 12B. Dosage and adverse effects of antimycobacterial drugs -- Table 13A. Treatment of parasitic infections -- Table 13B. Dosage and selected adverse effects of antiparasitic drugs -- Table 13C. Parasites that cause Eosinophilia (Eosinophilia in travelers) -- Table 13D. Sources for hard-to-find antiparasitic drugs -- Table 14A. Antiviral therapy -- Table 14B. Antiviral drugs (Non-HIV) -- Table 14C. Antiretroviral Therapy (ART) in treatment-naìˆve adults (HIV/AIDS) -- Table 14D. Antiretroviral drugs and adverse effects -- Table 14E. Hepatitis A & HBV treatment -- Table 14F. HCV treatment regimens and response -- Table 15A. Antimicrobial prophylaxis for selected bacterial infections -- Table 15B. Antibiotic prophylaxis to prevent surgical infections in adults -- Table 15C. Antimicrobial prophylaxis for the prevention of bacterial endocarditis in patients with underlying cardiac conditions -- Table 15D. Management of exposure to HIV-1 and Hepatitis B and C -- Table 15E. Prevention of selected opportunistic infections in Human Hematopoietic Cell Transplantation (HCT) or Solid Organ Transplantation (SOT) in adults with normal renal function -- Table 16. Pediatric dosing (Age >28 days) -- Table 17A. Dosage of antimicrobial drugs in adult patients with renal impairment -- Table 17B. No dosage adjustment with renal insufficiency by category -- Table 17C. Antimicrobial dosing in obesity -- Table 17D. No dosing adjustments required in obesity -- Table 18. Antimicrobials and hepatic disease: Dosage adjustment -- Table 19. Treatment of CAPD peritonitis in adults -- Table 20A. Anti-tetanus prophylaxis, wound classification, immunization -- Table 20B. Rabies postexposure prophylaxis -- Table 21. Selected directory of resources -- Table 22. Anti-infective drug-drug interactions -- Table 23. List of generic and trade names -- Index.

Online access:
No online access
Library holdings:
MCPHS Circulation - Manchester Campus
RM267 .S36 2021Available
  • Available Temporarily at MCPHS Manchester Reserve
MCPHS Circulation - Worcester Campus
RM267 .S26 2021Available